[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Alterity Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":16,"phases":4,"briefSummary":17,"conditions":18,"keywords":4,"overallStatus":20,"whyStopped":4,"lastUpdateSubmitDate":21,"lastUpdatePostDateStruct":22,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":25,"locationsCount":4},"100633803","post-trial-access-to-ath434-for-patients-with-multiple-system-atrophy-100633803",false,"NCT07531433","Post-Trial Access to ATH434 for Patients With Multiple System Atrophy","Inclusion Criteria:\n\n* Completed Alterity protocol ATH434-201 or ATH434-202\n* Expected to benefit from treatment from treatment with ATH434, in the opinion of the treating physician\n\nExclusion Criteria:\n\n* Discontinued prior ATH434 treatment (ATH434-201 or ATH434-202) for any reason\n* Significant medical or psychiatric condition that may decrease the benefit-risk ratio of participation in this program to an unacceptable level, as per the treating physician's opinion","ALL","EXPANDED_ACCESS","This multicenter post-trial access program is designed to provide ATH434 orally BID to eligible patients who completed Phase 2 studies ATH434-201 or ATH434-202, and who may benefit from this treatment according to the evaluation by their treating physicians.",[19],"Multiple System Atrophy","AVAILABLE","2026-04-09",{"date":23,"type":24},"2026-04-15","ACTUAL",{"name":26,"class":27},"Alterity Therapeutics","INDUSTRY",""]